Zevaquenabant

Zevaquenabant ((S) -MRI-1867) is a peripherally restricted, orally bioavailable dual cannabinoid CB1 receptor and inducible NOS antagonist. Zevaquenabant ameliorates obesity-induced chronic kidney disease (CKD) [1].

Product Specifications

CAS Number

[1998760-00-1]

Product Name Alternative

(S) -MRI-1867

UNSPSC

12352005

Target

Cannabinoid Receptor; NO Synthase

Type

Reference compound

Related Pathways

GPCR/G Protein; Immunology/Inflammation; Neuronal Signaling

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/zevaquenabant.html

Purity

99.64

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=S(/N=C(N1N=C(C2=CC=C(Cl)C=C2)[C@@H](C3=CC=CC=C3)C1)/N=C(N)/C)(C4=CC=C(C(F)(F)F)C=C4)=O

Molecular Formula

C25H21ClF3N5O2S

Molecular Weight

547.98

References & Citations

[1]Udi S, et al. Dual inhibition of cannabinoid CB1 receptor and inducible NOS attenuates obesity-induced chronic kidney disease [published correction appears in Br J Pharmacol. 2021 Mar;178 (5) :1250]. Br J Pharmacol. 2020;177 (1) :110-127.